Intercept Pharma (ICPT) Announces Design of OCA Phase 3 in NASH with Liver Fibrosis
Tweet Send to a Friend
Intercept Pharma (NASDAQ: ICPT) announced its plans for an international Phase 3 trial of obeticholic acid (OCA), the company's lead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
